- /
- Supported exchanges
- / US
- / MNMD.NASDAQ
Mind Medicine Inc (MNMD NASDAQ) stock market data APIs
Mind Medicine Inc Financial Data Overview
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Mind Medicine Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Mind Medicine Inc data using free add-ons & libraries
Get Mind Medicine Inc Fundamental Data
Mind Medicine Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -151 672 752
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -0.5
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Mind Medicine Inc News
New
What’s Driving JonesTrading’s Bullish View on Mind Medicine (MindMed) Inc. (MNMD)
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) is among the Best Get Rich Fast Stocks to Buy Right Now. According to TheFly, JonesTrading initiated coverage on Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) w...
Wall Street Thinks This 1 Psychedelic Stock Can Gain 335% in 2026
Mental health has moved from the margins to the center of the global healthcare conversation. Rising anxiety, depression, and treatment-resistant conditions are stretching traditional therapies to the...
Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades: T...
MarketBeat’s Top 5 Rated Small-Cap Stocks
Rising 2026 growth chart emerging over an industrial cityscape. Key Points Small-cap stocks are regaining momentum as rate cuts and the end of quantitative tightening drive a renewed risk-on environ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.